Cargando…
Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
The mechanisms by which SGLT‐2 inhibitors lower albuminuria are incompletely understood. We assessed in a post‐hoc analysis of a cross‐over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM‐1, NGAL and LFABP) a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055757/ https://www.ncbi.nlm.nih.gov/pubmed/29573529 http://dx.doi.org/10.1111/dom.13301 |
_version_ | 1783341240852414464 |
---|---|
author | Dekkers, Claire C. J. Petrykiv, Sergei Laverman, Gozewijn D. Cherney, David Z. Gansevoort, Ron T. Heerspink, Hiddo J. L. |
author_facet | Dekkers, Claire C. J. Petrykiv, Sergei Laverman, Gozewijn D. Cherney, David Z. Gansevoort, Ron T. Heerspink, Hiddo J. L. |
author_sort | Dekkers, Claire C. J. |
collection | PubMed |
description | The mechanisms by which SGLT‐2 inhibitors lower albuminuria are incompletely understood. We assessed in a post‐hoc analysis of a cross‐over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM‐1, NGAL and LFABP) and inflammatory markers (urinary MCP‐1 and IL‐6) to provide more insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI, 30.3%‐54.8%) and eGFR by 5.1 (2.0‐8.1) mL/min/1.73m(2) compared to placebo. Dapagliflozin did not change glomerular charge or size selectivity index compared to placebo. Dapagliflozin decreased urinary KIM‐1 excretion by 22.6% (0.3%‐39.8%; P = .05) and IL‐6 excretion by 23.5% (1.4%‐40.6%; P = .04) compared to placebo, whereas no changes in NGAL, LFABP and MCP‐1 were observed. During dapagliflozin treatment, changes in albuminuria correlated with changes in eGFR (r = 0.36; P = .05) and KIM‐1 (r = 0.39; P = .05). In conclusion, the albuminuria‐lowering effect of 6 weeks of dapagliflozin therapy may be the result of decreased intraglomerular pressure or reduced tubular cell injury. |
format | Online Article Text |
id | pubmed-6055757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60557572018-07-30 Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers Dekkers, Claire C. J. Petrykiv, Sergei Laverman, Gozewijn D. Cherney, David Z. Gansevoort, Ron T. Heerspink, Hiddo J. L. Diabetes Obes Metab Brief Reports The mechanisms by which SGLT‐2 inhibitors lower albuminuria are incompletely understood. We assessed in a post‐hoc analysis of a cross‐over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM‐1, NGAL and LFABP) and inflammatory markers (urinary MCP‐1 and IL‐6) to provide more insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI, 30.3%‐54.8%) and eGFR by 5.1 (2.0‐8.1) mL/min/1.73m(2) compared to placebo. Dapagliflozin did not change glomerular charge or size selectivity index compared to placebo. Dapagliflozin decreased urinary KIM‐1 excretion by 22.6% (0.3%‐39.8%; P = .05) and IL‐6 excretion by 23.5% (1.4%‐40.6%; P = .04) compared to placebo, whereas no changes in NGAL, LFABP and MCP‐1 were observed. During dapagliflozin treatment, changes in albuminuria correlated with changes in eGFR (r = 0.36; P = .05) and KIM‐1 (r = 0.39; P = .05). In conclusion, the albuminuria‐lowering effect of 6 weeks of dapagliflozin therapy may be the result of decreased intraglomerular pressure or reduced tubular cell injury. Blackwell Publishing Ltd 2018-04-23 2018-08 /pmc/articles/PMC6055757/ /pubmed/29573529 http://dx.doi.org/10.1111/dom.13301 Text en © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Brief Reports Dekkers, Claire C. J. Petrykiv, Sergei Laverman, Gozewijn D. Cherney, David Z. Gansevoort, Ron T. Heerspink, Hiddo J. L. Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers |
title | Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers |
title_full | Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers |
title_fullStr | Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers |
title_full_unstemmed | Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers |
title_short | Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers |
title_sort | effects of the sglt‐2 inhibitor dapagliflozin on glomerular and tubular injury markers |
topic | Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055757/ https://www.ncbi.nlm.nih.gov/pubmed/29573529 http://dx.doi.org/10.1111/dom.13301 |
work_keys_str_mv | AT dekkersclairecj effectsofthesglt2inhibitordapagliflozinonglomerularandtubularinjurymarkers AT petrykivsergei effectsofthesglt2inhibitordapagliflozinonglomerularandtubularinjurymarkers AT lavermangozewijnd effectsofthesglt2inhibitordapagliflozinonglomerularandtubularinjurymarkers AT cherneydavidz effectsofthesglt2inhibitordapagliflozinonglomerularandtubularinjurymarkers AT gansevoortront effectsofthesglt2inhibitordapagliflozinonglomerularandtubularinjurymarkers AT heerspinkhiddojl effectsofthesglt2inhibitordapagliflozinonglomerularandtubularinjurymarkers |